Switching to DrugPatentWatch
Don’t wait until the end of the year to start looking for alternatives to your existing business intelligence providers. DrugPatentWatch […]
Insights
Government as the First Investor in Biopharmaceutical Innovation
Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at
Government as the First Investor in Biopharmaceutical Innovation Read Post »
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Finding hidden treasures in old drugs: the challenges and importance of licensing generics
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris
Drug Repurposing: An Overview
This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal
Investing in Drug Companies? Here are 6 Vital Non-Patent Factors to Consider
When drug patents expire, billions of dollars in revenues can disappear overnight as competitors enter the market. Accordingly, many investors
Investing in Drug Companies? Here are 6 Vital Non-Patent Factors to Consider Read Post »
Generic Drugs Approved but not Launched – How to Tell When Generic Drugs Will hit the Market
Just because a drug has received FDA approval does not mean that it is available in the marketplace. But, why
Free Patent Litigation Docket Reports Data
The USPTO Office of the Chief Economist has releases a comprehensive set of patent litigation data files for public use.
Featured, Insights
Free Orange Book PDF Library from DrugPatentWatch
The FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations, is the definitive source to link drugs with
Free Orange Book PDF Library from DrugPatentWatch Read Post »
